Annotation of rs2306283

Allele G is not associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele A.

From Publication

The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir. Pharmacogenomics. 2019. Guo Zifang et al.
PMID:31250727(opens in new window) DOI:10.2217/pgs-2019-0022(opens in new window)

Gene

SLCO1B1

Variant

rs2306283

Phenotype Category

PD

Association Significance

The study reports this association is not significant

PharmGKB ID

1450934582

Score
More info on scoring

-0.75

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    clinical trial, meta-analysis, retrospective

    Study size

    1561

    Association p-value

    = 0.3803

    Allele frequency

    G=0.534

    Biogeographical group
    More info on groups

    Multiple groups, This is a retrospective pharmacogenetic analysis of a pooled dataset of selected HCV GT1- or GT4-infected participants enrolled in ten Phase II/III clinical trials of EBR/GZR: C-WORTHY (MSD Protocol, 5172-035; ClinicalTrials. gov identifier NCT01717326), C-SCAPE (5172-047; NCT01932762), C-SALVAGE (5172-048; NCT02105454), C-SURFER (5172-052; NCT02092350), Japan Phase II/III study (5172-058; NCT02203149), C-SALT (5172-059; NCT02115321), C-EDGE Treatment-Naive (5172-060; NCT02105467), C-EDGE CO-INFECTION (5172-061; NCT02105662), C-EDGE CO-STAR (5172-062; NCT02105688), C-EDGE Treatment-Experienced (5172-068; NCT02105701)

    Population description

    men; women

    Drug: AUC(0-24)

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    No history available.